Sodium Valproate

(asked on 20th July 2020) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Independent Medicines and Medical Devices Safety Review by Baroness Cumberlege, what the planned timescale is for implementing recommendations 1,2,3 4, and 6 of that report with regard to sodium valproate.


Answered by
Nadine Dorries Portrait
Nadine Dorries
This question was answered on 15th August 2020

The Medicines and Healthcare products Regulatory Agency (MHRA) is working with stakeholders to improve compliance with the valproate Pregnancy Prevention Programme which aims to rapidly reduce and eventually eliminate pregnancies exposed to valproate. The MHRA is also working on developing a valproate registry, the main aims of which would be to monitor the use of valproate in girls and women in the United Kingdom and compliance with the current regulatory position, and to identify and monitor any children born to women on valproate.

The Department is carefully considering the recommendations of the Independent Medicines and Medical Devices Safety Review and will respond in due course.

Reticulating Splines